Valneva (VALN) announced that the United States Food and Drug Administration, FDA, has suspended the license for IXCHIQ, citing four new reports of serious adverse events, SAEs, consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ in the United States. The suspension follows the FDA’s decision on August 6, 2025 to remove its recommended pause in the use of IXCHIQ in individuals 60 years of age and older based on a thorough investigation of reported SAEs, primarily among elderly individuals with multiple underlying health conditions.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva Faces FDA Suspension of Chikungunya Vaccine License
- Valneva SE (ADR) trading halted, news pending
- Valneva’s Promising Future: Buy Rating Backed by VLA15 Vaccine and Robust Portfolio
- Valneva assumed with a Buy at H.C. Wainwright
- Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval